They found that the modified OMVs specifically target tumor tissue in vivo, triggering interferon-γ (IFN-γ) and C-X-C motif chemokine ligand 10 (CXCL10) to stimulate a strong, sustained immune response that clears tumors. This evidence concerns the gene CXCL10 and neoplasm.